{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AFLIBERCEPT+AVE0005&page=4",
    "query": {
      "intervention": "AFLIBERCEPT AVE0005",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 268,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AFLIBERCEPT+AVE0005&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AFLIBERCEPT+AVE0005&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T17:00:35.054Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05930561",
      "title": "4D-150 in Patients With Diabetic Macular Edema",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aflibercept IVT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2023-08-09",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 5,
      "location_summary": "Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05930561"
    },
    {
      "nct_id": "NCT05640895",
      "title": "Intravitreal Injection Site and Perceived Pain",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Intravitreal injection site",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 53,
      "start_date": "2022-11-14",
      "completion_date": "2024-09-09",
      "has_results": false,
      "last_update_posted_date": "2025-01-31",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05640895"
    },
    {
      "nct_id": "NCT04469595",
      "title": "A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Iluvien 0.19 MG Drug Implant",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alimera Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2020-08-31",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04469595"
    },
    {
      "nct_id": "NCT06856577",
      "title": "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)",
        "Wet AMD"
      ],
      "interventions": [
        {
          "name": "Ixo-vec",
          "type": "GENETIC"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2025-02-28",
      "completion_date": "2030-11-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 75,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06856577"
    },
    {
      "nct_id": "NCT00789477",
      "title": "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Laser Photocoagulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2008-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-09-09",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 42,
      "location_summary": "Artesia, California • Beverly Hills, California • Mountain View, California + 38 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00789477"
    },
    {
      "nct_id": "NCT02732899",
      "title": "Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exudative Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "EYLEA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maturi, Raj K., M.D., P.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-04",
      "completion_date": "2017-04-04",
      "has_results": true,
      "last_update_posted_date": "2018-02-14",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02732899"
    },
    {
      "nct_id": "NCT02214628",
      "title": "Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Fovista® (anti-PDGF BB) plus anti-VEGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2014-07",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214628"
    },
    {
      "nct_id": "NCT06850922",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "RO7446603",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Faricimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 388,
      "start_date": "2022-06-22",
      "completion_date": "2026-06-19",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 70,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06850922"
    },
    {
      "nct_id": "NCT03810313",
      "title": "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Brolucizumab 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 493,
      "start_date": "2019-07-03",
      "completion_date": "2021-07-26",
      "has_results": true,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03810313"
    },
    {
      "nct_id": "NCT01579760",
      "title": "Intravitreal Aflibercept Injection for Radiation Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiation Retinopathy",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "Aflibercept every 2 months",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept monthly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-11",
      "completion_date": "2019-03-27",
      "has_results": false,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-10-06T17:00:35.054Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579760"
    }
  ]
}